RxNorm Semantic Concepts Index - 839
What is RxNorm?
RxNorm is a system developed and maintained by the National Library of Medicine (NLM). RxNorm is a normalized naming system for generic and branded drugs. RxNorm is also a tool that supports interoperability between different drug terminologies and other naming systems.
The following table is a complete listing of RxNorm concepts whose unique RxCUI identifier starts with "839".
RxCUI | Name | Term Type | Term Type Description | Is Prescribable? |
---|---|---|---|---|
RxCUI: 839 | Angiotensin | Designated preferred name (PT) | NO | |
RxCUI: 839 | Angiotensin | Full form of descriptor (FN) | NO | |
RxCUI: 8390 | Plant agent | Synonym (SY) | Synonym of another TTY, given for clarity. | NO |
RxCUI: 8390 | Plant agent | Full form of descriptor (FN) | NO | |
RxCUI: 8390 | Plant agent | Designated preferred name (PT) | NO | |
RxCUI: 83929 | abciximab | Ingredient (IN) | A compound or moiety that gives the drug its distinctive clinical properties. Ingredients generally use the United States Adopted Name (USAN). | NO |
RxCUI: 83929 | abciximab | Designated preferred name (PT) | NO | |
RxCUI: 83929 | abciximab | Full form of descriptor (FN) | NO | |
RxCUI: 83929 | abciximab | Designated preferred name (PT) | NO | |
RxCUI: 83929 | abciximab | Full form of descriptor (FN) | NO | |
RxCUI: 83947 | tazarotene | Full form of descriptor (FN) | YES | |
RxCUI: 83947 | tazarotene | Ingredient (IN) | A compound or moiety that gives the drug its distinctive clinical properties. Ingredients generally use the United States Adopted Name (USAN). | YES |
RxCUI: 83947 | tazarotene | Designated preferred name (PT) | YES | |
RxCUI: 83947 | tazarotene | Full form of descriptor (FN) | YES | |
RxCUI: 83947 | tazarotene | Designated preferred name (PT) | YES | |
RxCUI: 8397 | Plasma | Designated preferred name (PT) | NO | |
RxCUI: 8397 | Plasma | Full form of descriptor (FN) | NO | |
RxCUI: 8397 | Plasma | Designated preferred name (PT) | NO | |
RxCUI: 8397 | Plasma | Full form of descriptor (FN) | NO |